Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Avrobio Inc (NQ: AVRO ) 1.390 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Avrobio Inc < Previous 1 2 3 4 5 6 Next > AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Leadership Transition May 01, 2023 From AVROBIO, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session March 23, 2023 Via Benzinga AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update March 23, 2023 From AVROBIO, Inc. Via Business Wire Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy December 07, 2022 Via Benzinga Recap: Avrobio Q2 Earnings August 09, 2022 Avrobio (NASDAQ:AVRO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference March 03, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023 February 09, 2023 From AVROBIO, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session January 10, 2023 Via Benzinga AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 05, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023' December 07, 2022 New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3... Via Benzinga AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy December 07, 2022 From AVROBIO, Inc. Via Business Wire Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment November 29, 2022 Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, Via Benzinga AVROBIO to Share Comprehensive Gaucher Disease Program Update November 17, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update November 08, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit November 07, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 03, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease October 27, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis October 25, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease October 18, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development October 11, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 06, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress September 27, 2022 From AVROBIO, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session September 20, 2022 Via Benzinga Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions September 20, 2022 As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... Via Benzinga AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis September 20, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial September 14, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 08, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Participate in Four Upcoming Investor Conferences in September August 31, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From AVROBIO, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.